ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,905.11
-1.10%
Dow Jones
42,544.83
-1.04%
US Dollar vs MXN
20.5045
0.89%
Brent Oil
74.025
0.54%
Bitcoin
91,885.51
-1.75%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Gilead Sciences Inc (GILD) Cotización

Gilead Sciences Inc

Gilead Sciences Inc (GILD)

DMG Mori AG
DMG Mori AG
DMG Mori AG
DMG Mori AG
Guild Esports Plc
92.18
-1.93
( -2.05% )
Actualizado: 10:15:32
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
92.18
Postura de Compra
92.18
Postura de Venta
92.19
Volume Operado de la Acción
817,390
91.72 Rango del Día 94.02
62.07 Rango de 52 semanas 98.90
Capitalización de Mercado [m]
114.881B
Precio Anterior
94.11
Precio de Apertura
93.93
Hora
1
@
92.18
Última hora de negociación
10:15:34
Volumen financiero
US$ 75,295,116
Precio Promedio Ponderado
92.1165
Volumen promedio (3 m)
6,580,600
Acciones en circulación
1,246,265,857
Rendimiento del Dividendo
3.34%
Ratio Precio/Utilidad
20.23
Beneficio por acción (BPA)
4.55
turnover
27.12B
Beneficio neto
5.67B

Acerca de Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.gilead.com
Sede
Wilmington, Delaware, USA
Fundado
-
Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was US$94.11. Over the last year, Gilead Sciences shares have traded in a share price range of US$ 62.07 to US$ 98.90.

Gilead Sciences currently has 1,246,265,857 shares in issue. The market capitalisation of Gilead Sciences is US$117.29 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 20.23.

Flujo de Opciones Gilead Sciences (GILD)

Ver flujo de opciones completo

Flujo General

Optimista

Prima Neta

321k

Calls / Puts

200.00%

Comp. / Vent.

50.00%

OTM / ITM

200.00%

Sweeps Ratio

0.00%

GILD Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities

23 Diciembre 2024
Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

23 Diciembre 2024
Edgar (US Regulatory)

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025...

20 Diciembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

19 Diciembre 2024
Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

19 Diciembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

17 Diciembre 2024
Edgar (US Regulatory)

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for...

17 Diciembre 2024
Business Wire

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- -- Gilead Has Exclusive Option to Develop and...

17 Diciembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

16 Diciembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

16 Diciembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.44-0.47505938242392.6294.5591.72329958893.89182287CS
4-0.47-0.50728548300192.6594.6589.15726930992.37116698CS
127.138.3833039388685.0598.984.165658060090.87127798CS
2623.5234.255752985768.6698.966.01650076783.77320194CS
5211.2713.929056976980.9198.962.07706318277.36372261CS
15618.516525.136600894673.663598.957.165714582973.72853348CS
26026.4540.240377301165.7398.956.56842829371.73667086CS

GILD - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Gilead Sciences?
El precio actual de las acciones de Gilead Sciences es US$ 92.18
¿Cuántas acciones de Gilead Sciences están en circulación?
Gilead Sciences tiene 1,246,265,857 acciones en circulación
¿Cuál es la capitalización de mercado de Gilead Sciences?
La capitalización de mercado de Gilead Sciences es USD 117.29B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Gilead Sciences?
Gilead Sciences ha negociado en un rango de US$ 62.07 a US$ 98.90 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Gilead Sciences?
El ratio precio/beneficio de Gilead Sciences es 20.23
¿Cuál es el ratio de efectivo a ventas de Gilead Sciences?
El ratio de efectivo a ventas de Gilead Sciences es 4.23
¿Cuál es la moneda de reporte de Gilead Sciences?
Gilead Sciences presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Gilead Sciences?
El último ingresos anual de Gilead Sciences es USD 27.12B
¿Cuál es el último beneficio anual de Gilead Sciences?
El último beneficio anual de Gilead Sciences es USD 5.67B
¿Cuál es la dirección registrada de Gilead Sciences?
La dirección registrada de Gilead Sciences es 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Gilead Sciences?
La dirección del sitio web de Gilead Sciences es www.gilead.com
¿En qué sector industrial opera Gilead Sciences?
Gilead Sciences opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NXUNXU Inc
US$ 0.9792
(302.30%)
293.08M
WATTEnergous Corporation
US$ 1.54
(274.51%)
149.42M
INTZIntrusion Inc
US$ 5.55
(156.94%)
101.29M
CYNCYNGN Inc
US$ 1.53
(143.67%)
39.66M
VINCVincerx Inc
US$ 0.390884
(101.49%)
264.04M
ABPAbpro Holdings Inc
US$ 2.26
(-49.67%)
849.35k
TRAWTraws Pharma Inc
US$ 8.26
(-38.45%)
775.43k
LITMSnow Lake Resources Ltd
US$ 1.1792
(-26.30%)
40.09M
BITSGlobal X Blockchain and Bitcoin Stratagy ETF
US$ 66.34
(-25.01%)
7.1k
NVNINVNI Group Ltd
US$ 3.28
(-22.09%)
272.3k
NXUNXU Inc
US$ 0.9792
(302.30%)
296.49M
VINCVincerx Inc
US$ 0.390884
(101.49%)
264.37M
WATTEnergous Corporation
US$ 1.54
(274.51%)
150.16M
XTIAXTI Aerospace Inc
US$ 0.04039
(2.25%)
148.33M
INTZIntrusion Inc
US$ 5.55
(156.94%)
102.78M

GILD Discussion

Ver más
jondoeuk jondoeuk 4 semanas hace
They now add an investigational HIV vaccine to its portfolio https://www.fiercebiotech.com/biotech/gilead-buys-hiv-vaccine-spanish-biotech-following-success-clinical-collab

Data on the vaccine in combination with vesatolimod https://www.ddw-online.com/hiv-combination-regimen-could-lead-to-viral-remission-22215-202302/
👍️0
jondoeuk jondoeuk 4 semanas hace
Based on recent data*, I would have thought that getting KITE-509 into the clinic (for GPC3+ solid tumours, not just 3L+ HCC) would be a priority.

* https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019 https://www.nature.com/articles/s41586-024-08261-8
👍️0
fink fink 1 mes hace
CEO is talking now.
The stock is selling off on great words.
Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

They should be allowed to make a buck or two.
I want $250 a share please, I've held it way too long.
👍️0
Monksdream Monksdream 2 meses hace
GILD, 10Q 11/6
👍️0
Monksdream Monksdream 2 meses hace
GILD a new 52 week high
👍️0
Monksdream Monksdream 2 meses hace
GILD new 52=week high
👍️0
jondoeuk jondoeuk 2 meses hace
Two years later, and here are some of my takeaways...

- They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

- Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is
👍️0
jondoeuk jondoeuk 2 meses hace
''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine
👍️0
jondoeuk jondoeuk 2 meses hace
https://x.com/JackSha90859576/status/1847728103021281381
👍️0
TechandBio TechandBio 3 meses hace
Wants to go higher!

$GILD
👍️0
Monksdream Monksdream 4 meses hace
GILD approaching a 52 week high
👍️0
north40000 north40000 4 meses hace
Featured on CNBC-TV this morning, 8:40 a.m. time frame.
👍️0
TechandBio TechandBio 5 meses hace
NICE!

clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

$GILD
👍️0
TechandBio TechandBio 5 meses hace
Adding shares and calls under $80..00

HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.



$GILD
$GILD
👍️0
midastouch017 midastouch017 5 meses hace
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

FDA clearance triggers a $30 million milestone payment from Gilead
👍️0
Monksdream Monksdream 5 meses hace
GILD under $100
👍️0
TechandBio TechandBio 5 meses hace
Target is $100-$120 by Q2 2025

$GILD
👍️0
TechandBio TechandBio 5 meses hace
HIV Prevention CURE Shot 2x a year

Great growing oncology pipeline!

my $80 vertical Calls from last week are looking golden!

$GILD
👍️0
north40000 north40000 7 meses hace
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

"Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
👍️0
north40000 north40000 7 meses hace
How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
👍️0
jondoeuk jondoeuk 7 meses hace
There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
👍️0
jondoeuk jondoeuk 7 meses hace
A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
👍️0
jondoeuk jondoeuk 7 meses hace
They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
👍️0
jondoeuk jondoeuk 7 meses hace
''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
👍️0
jondoeuk jondoeuk 7 meses hace
The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
👍️0
jondoeuk jondoeuk 8 meses hace
The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
👍️0
jondoeuk jondoeuk 9 meses hace
IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
👍️0
jondoeuk jondoeuk 9 meses hace
Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
👍️0
jondoeuk jondoeuk 9 meses hace
Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
👍️0
jondoeuk jondoeuk 9 meses hace
I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
👍️0
jondoeuk jondoeuk 9 meses hace
Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
👍️0
Monksdream Monksdream 11 meses hace
GILD new 52 week high
👍️0
jondoeuk jondoeuk 1 año hace
Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
👍️0
jondoeuk jondoeuk 1 año hace
Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them
👍️0
jondoeuk jondoeuk 1 año hace
The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
👍️0
Greedy G Greedy G 1 año hace
~bought 9/22 $80 calls .08c
👍️0
jondoeuk jondoeuk 2 años hace
Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
👍️0
DewDiligence DewDiligence 2 años hace
Why is an oral prodrug of Remdesivir anything to get excited about?
👍️0
jondoeuk jondoeuk 2 años hace
Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
👍️0
jondoeuk jondoeuk 2 años hace
Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
👍️0
fink fink 2 años hace
Christmas sell off over, last day to lock in any paper tax loss. LOL

Who’s losing money here?

I think we start the trend back up into Q1
👍️0
fink fink 2 años hace
It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
👍️0
PennyPusher786 PennyPusher786 2 años hace
It's at a 3 year high
👍️0
fung_derf fung_derf 2 años hace
Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
👍️0
fink fink 2 años hace
Nice to see GILD over $80

Wonder if I should trim some? It’s been eating chit pie for some time.
Still don’t see why the spike.
👍️0
jondoeuk jondoeuk 2 años hace
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
👍️0
Zeppo Zeppo 3 años hace
Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
👍️0
DewDiligence DewDiligence 3 años hace
GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

The viewpoint in #msg-158260565 (from 2020) has not changed.
👍️0
mick mick 3 años hace
Gilead Sciences Inc (GILD)
59.77 ? -1.79 (-2.91%)
Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
Bid Ask Day's Range
59.53 60.0 59.27 - 62.06
GILD Detailed Quote
👍️0
jondoeuk jondoeuk 3 años hace
ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




👍️0

Su Consulta Reciente

NASDAQ
GILD
Gilead Sciences
NYSE
SYK
Stryker
BIT
NSCIT2236023
IBRD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados